Pfizer to invest $20 million in CytoReason

Pfizer to invest $20 million in CytoReason

San Francisco, 9/25/2022

Pfizer will invest $20 million in CytoReason, a disease modeling platform that accelerates drug discovery using AI. The investment is part of a broader deal between the companies that amounts to up to $110 million over five years.

The pharma giant will start with a $20 million equity investment and then distribute up to $90 million by 2027. The agreement extends a collaboration between the two companies signed three years ago.

Under the agreement, Pfizer has the option to license CytoReason’s platform and models and fund additional research projects and disease models in new therapeutic areas.

CytoReason’s platform collects data from multiple sources to simulate disease on models of human tissue or cells. can help pharmaceutical companies predict how drugs will affect the human body, which could accelerate the discovery of new drugs and potentially bring them to market at a lower cost.

With the help of AI, the response can be predicted instead of waiting for clinical trials in animals and humans.